Loading institutional data...
Loading institutional data...
Strong institutional accumulation: ownership increased +7.12% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $8.45 today, the market must believe free cash flow compounds 16.1%/yr for a decade (off $4M normalized FCF).
The market's 16.1% is more optimistic than its 9-yr track record.
2-stage DCF · 0.03B shares · net debt -$67M
mean -34.9% · volatility σ 184% · implied rate exceeded in 2/6 yrs
Central path = implied 16.1%/yr growth; shaded band = ±1σ (184%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
EOD close · as of 2026-09-14
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $245.7M 100.0% | $148.1M 100.0% | $54.4M 100.0% | $30.6M 100.0% | $27.4M 100.0% | $45.1M 100.0% | $32.8M 100.0% | $22.3M 100.0% | $18.3M 100.0% | $27.4M 100.0% |
| Cost of Revenue | $213.3M 86.8% | $125.8M 84.9% | $43.4M 79.8% | $21.7M 70.7% | $21.0M 76.8% | $38.3M 84.9% | $26.2M 79.9% | $13.9M 62.0% | — | — |
| Cost of Services | — | — | — | — | — | — | — | $13.9M 62.0% | $10.6M 57.8% | $20.2M 73.7% |
| Gross Profit | $32.4M 13.2% | $22.4M 15.1% | $11.0M 20.2% | $9.0M 29.3% | $6.4M 23.2% | $6.8M 15.1% | $6.6M 20.1% | $8.5M 38.0% | $7.7M 42.2% | $7.2M 26.3% |
| Selling, General & Admin | $20.6M 8.4% | $13.2M 8.9% | $8.9M 16.4% | $7.7M 25.1% | $6.7M 24.3% | $6.7M 14.8% | $5.7M 17.5% | $6.4M 28.5% | $6.5M 35.3% | $8.1M 29.8% |
| Total Operating Expenses | $26.1M 10.6% | $16.6M 11.2% | $11.2M 20.6% | — | — | — | — | — | — | — |
| Operating Income | $6.3M 2.6% | $5.8M 3.9% | -$221K -0.4% | $914K 3.0% | -$831K -3.0% | -$400K -0.9% | $480K 1.5% | $2.9M 12.8% | $1.1M 6.0% | -$633K -2.3% |
| Interest Expense | — | $2.7M 1.8% | $2.0M 3.6% | $931K 3.0% | $430K 1.6% | $367K 0.8% | $313K 1.0% | $403K 1.8% | $328K 1.8% | $365K 1.3% |
| Interest & Investment Income | $1.7M 0.7% | $562K 0.4% | $0 0.0% | — | — | — | — | — | — | — |
| Other Income (Expense), net | — | $194K 0.1% | $0 0.0% | $33K 0.1% | $29K 0.1% | $896K 2.0% | — | — | -$3K -0.0% | -$6K -0.0% |
| Pretax Income | $7.5M 3.1% | $6.1M 4.1% | $134K 0.2% | -$17K -0.1% | -$1.2M -4.5% | $129K 0.3% | $167K 0.5% | $2.5M 11.0% | $775K 4.2% | -$1.0M -3.7% |
| Income Tax Expense | -$7.6M -3.1% | $158K 0.1% | $60K 0.1% | $56K 0.2% | $65K 0.2% | $50K 0.1% | $41K 0.1% | $26K 0.1% | $9K 0.0% | $19K 0.1% |
| Net Income | $15.1M 6.2% | $6.0M 4.0% | $74K 0.1% | -$73K -0.2% | -$1.3M -4.7% | $79K 0.2% | $126K 0.4% | $2.4M 10.9% | $766K 4.2% | -$1.0M -3.7% |
| Per Share | ||||||||||
| EPS (Basic) | $0.61 | $0.27 | $0.00 | $0.00 | $-0.07 | $0.00 | $0.01 | $0.16 | $0.05 | $-0.07 |
| EPS (Diluted) | $0.56 | $0.24 | $0.00 | $0.00 | $-0.07 | $0.00 | $0.01 | $0.13 | $0.05 | $-0.07 |
| Weighted Avg Shares (Basic) | — | — | 21.6M | 20.1M | 18.4M | 17.8M | 17.4M | 15.5M | 15.5M | 15.4M |
| Weighted Avg Shares (Diluted) | 27.2M | 25.1M | 22.0M | 20.1M | 18.4M | 21.0M | 20.9M | 18.7M | 16.5M | 15.4M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Cash conversion lags reported earnings — watch accruals. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $5M buybacks = $5M returned on $2M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Insufficient data. Current ROIC on all capital: 16%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $86M covers all $37M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Coverage is adequate but not comfortable. Effective rate ~33.4% on $8M of debt. Interest last disclosed in FY2024 (no longer broken out).
Cash of $86M fully covers short-term debt of $4M.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-14
No material risks flagged.
Where each multiple sits in its own 14-yr range · 62th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 62.0 | 79.9 | 84.9 | 76.8 | 70.7 | 79.8 | 84.9 | 86.8 |
| Gross Profit | 38.0 | 20.1 | 15.1 | 23.2 | 29.3 | 20.2 | 15.1 | 13.2 |
| SG&A | 28.5 | 17.5 | 14.8 | 24.3 | 25.1 | 16.4 | 8.9 | 8.4 |
| Operating Income | 12.8 | 1.5 | -0.9 | -3.0 | 3.0 | -0.4 | 3.9 | 2.6 |
| Income Tax | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.1 | 0.1 | -3.1 |
| Net Income | 10.9 | 0.4 | 0.2 | -4.7 | -0.2 | 0.1 | 4.0 | 6.2 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on TSSI: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 743 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TSM | $10.84T | — | — | — | — | — | — | — | — | — | 3,121 |
| NVDA | $5.13T | 43.0× | 38.5× | 23.7× | 65.5% | 71.1% | 55.6% | 76.3% | 72.4% | 0.1× | 5,582 |
| AAPL | $4.92T | 44.6× | 34.4× | 11.8× | 6.4% | 46.9% | 26.9% | 152% | 68.1% | 0.6× | 5,858 |
| MSFT | $3.75T | 28.2× | 19.9× | 11.3× | 17.8% | 67.9% | 40.3% | 30.2% | 27.7% | 0.2× | 5,944 |
| AVGO | $1.63T | 72.3× | 64.6× | 25.6× | 23.9% | 67.8% | 36.2% | 28.4% | 15.8% | 2.5× | 4,442 |
| MU | $1.04T | 121.7× | 57.4× | 27.7× | 48.9% | 39.8% | 22.8% | 15.8% | 12.9% | 0.7× | 2,894 |
| AMD | $804.3B | 186.2× | 190.3× | 23.2× | 34.3% | 49.5% | 12.5% | 6.9% | 6.5% | 0.8× | 3,059 |
| INTC | $485.4B | — | 60.6× | 9.2× | -0.5% | 34.8% | -0.5% | -0.2% | -0.2% | 5.5× | 2,495 |
| CSCO | $435.8B | 43.2× | 36.6× | 7.7× | 5.3% | 64.9% | 18.0% | 21.7% | 13.6% | 2.3× | 3,560 |
| PLTR | $414.4B | 275.1× | 286.8× | 92.6× | 56.2% | 82.4% | 36.3% | 22.0% | 22.0% | — | 2,883 |
| DELL | $348.4B | 61.5× | 33.0× | 3.1× | 18.8% | 20.0% | 5.2% | -240% | 20.4% | 2.8× | 1,564 |
| LRCX | $347.0B | 65.9× | 55.4× | 18.8× | 23.7% | 48.7% | 29.1% | 54.3% | 37.4% | 0.7× | 2,500 |
| AMAT | $336.4B | 49.0× | 38.7× | 11.9× | 4.4% | 48.7% | 24.7% | 34.3% | 25.9% | 0.8× | 2,826 |
| RPAY | $316.6B | — | — | 1023.6× | -1.2% | 75.0% | -83.0% | -53.0% | -28.2% | -1.7× | 142 |
| UMC | $275.1B | — | — | — | — | — | — | — | — | — | 302 |
| SAP | $268.2B | — | — | — | — | — | — | — | — | — | 794 |
| ARM | $254.3B | 281.2× | 218.9× | 51.7× | 22.8% | 97.5% | 18.4% | 10.9% | 10.9% | — | 730 |
| PANW | $249.8B | 233.7× | 156.0× | 27.1× | 14.9% | 73.4% | 12.3% | 14.5% | 14.5% | — | 2,374 |
| CRM | $241.0B | 33.3× | 26.0× | 5.8× | 9.6% | 77.7% | 18.0% | 12.6% | 10.1% | 1.5× | 2,547 |
| TXN | $239.4B | 48.3× | 31.5× | 13.5× | 13.0% | 57.0% | 28.3% | 30.7% | 16.5% | 1.8× | 2,345 |
| ANET | $236.0B | 68.3× | 59.6× | 26.2× | 28.6% | 64.1% | 39.0% | 28.4% | 28.4% | — | 1,930 |
| IBM | $233.4B | 22.3× | — | 3.5× | 7.6% | 58.2% | 15.7% | 32.4% | 11.3% | — | 3,351 |
| SNDK | $226.6B | — | — | 30.8× | 10.4% | 30.1% | -22.3% | -17.8% | -14.8% | -1.5× | 1,127 |
| QCOM | $193.5B | 36.0× | 14.5× | 4.4× | 13.7% | 55.4% | 12.5% | 26.1% | 15.4% | 1.1× | 2,611 |
| MRVL | $185.4B | 71.3× | 121.2× | 22.6× | 42.1% | 51.0% | 32.6% | 18.7% | 14.2% | 2.9× | 1,477 |
| TSSI | $233M | 15.1× | 16.4× | 0.9× | 65.9% | 13.2% | 6.2% | 19.7% | 16.0% | 1.8× | 111 |
Peers = companies sharing TSSI's sector (Technology) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.